Immunotherapy of acute myeloid leukemia: current approaches.
Following standard therapy that consists of chemotherapy with or without stem cell transplantation, both relapsed and refractory disease shorten the survival of acute myeloid leukemia (AML) patients. Therefore, additional treatment options are urgently needed, especially to fight residual AML cells. The identification of leukemia-associated antigens and the observation that administration of allogeneic T cells can mediate a graft-versus-leukemia effect paved the way to the development of active and passive immunotherapy strategies, respectively. The aim of these strategies is the eradication of AML cells by the immune system. In this review, an overview is provided of both active and passive immunotherapy strategies that are under investigation or in use for the treatment of AML. For each strategy, a critical view on the state of the art is given and future perspectives are discussed.
Smits
Evelien L J M
EL
Vaccine & Infectious Disease Institute (VIDI), Laboratory of Experimental Hematology, Faculty of Medicine, University of Antwerp, Antwerp, Belgium.
Berneman
Zwi N
ZN
Van Tendeloo
Viggo F I
VF
D000208:Acute Disease; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007951:Leukemia, Myeloid / Q000276:immunology / Q000628:therapy*